Rep. Mike Rogers praises BioThrax contract

U.S. Representative Mike Rogers (R–Michigan) recently issued a statement in praise of the U.S. Centers for Disease Control and Prevention’s decision to award a five year contract to Emergent BioSolutions, Inc.

The contract, estimated to be worth more than $1 billion over the five year period, calls for 44.75 million doses of the anthrax vaccine BioThrax to be delivered to the CDC’s Strategic National Stockpile.

"Yesterday’s announcement is great news for Lansing and for jobs in Michigan,” Rogers said. “Emergent currently produces the only FDA-approved vaccine for treating anthrax poisoning, and this contract will strengthen our national vaccine stockpile to protect the public against an attack.

"Anthrax remains the single largest bioterror threat to the United States, and the Lansing facility and its employees are essential partners with the federal government in building a strong emergency preparedness structure,” he continued. “I am pleased that the CDC has provided a long-term commitment to the 450 skilled workers in Lansing."

In 2006, Rogers authored the law that created the Biomedical Advanced Research and Development Authority. BARDA has been a key player in the federal effort to develop and purchase vaccines and diagnostic tools that prepare the United States against the threat of bioterrorism.

BioThrax is indicated for the immunization of adults with a high risk of exposure to anthrax. It is manufactured from a non-virulent strain of the bacteria Bacillus anthracis.

Emergent BioSolutions, Inc., has already delivered 42 million doses of the vaccine to the U.S. government and continues to do so under existing procurement contracts. Since 1998, 2.5 million military personnel have received 10 million doses of the vaccine.